Phase 2CompletedAge-related condition
A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Subjects With Type 2 Diabetes
- Sponsor
- NovMetaPharma Co., Ltd. (Industry)
- Enrolment
- 256 enrolled
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Cyclo-Z; Placebo
- Ages
- adults, older adults
- Registry
- NCT03560271
Full record on ClinicalTrials.gov
From the registry
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes. Approximately 20 clinical sites may be utilized in the United States so that approximately 300 subjects (a potential 20% screening failure rate) may be screened for total 28-week study period (2 weeks for screening, 24 weeks for treatment, and 2 weeks for safety follow-up).
Primary outcomes
- Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24
History
Last registry update
Study completion
Primary completion
Registered
Started